Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs

FDA’s review confirms use of Negative Binomial model for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease; results still expected in first quarter of 2021Company...
November 16, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
November 04, 2020 16:17 ET | Source: Otonomy, Inc.

Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Enrollment completed in Phase 3 clinical trial of OTIVIDEX® in Ménière’s disease with results expected in the first quarter of 2021Positive results reported for Phase 1/2 clinical trial of OTO-313 in...
October 28, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update

SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
October 02, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménière’s Disease

SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
September 02, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in Four Upcoming Investor Conferences

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
August 04, 2020 16:22 ET | Source: Otonomy, Inc.

Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Positive top-line results reported for Phase 1/2 trial of OTO-313 in tinnitus patientsPublic offering completed for total gross proceeds of $69.1 millionResults from Phase 3 trial of OTIVIDEX® in...
August 03, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an...
July 28, 2020 16:05 ET | Source: Otonomy, Inc.

Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update

SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
July 13, 2020 16:01 ET | Source: Otonomy, Inc.

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right